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Novel antifungals
Current available therapy for treating fungal infections can suffer from drug-related toxicity,
hazardous drug-drug interactions, non-optimal pharmacokinetics and the development of drug
resistance. Enzymes in the ergosterol-biosynthesis pathway, specifically the lanosterol 14-α
demethylase, are the targets for successful marketed antifungal drugs.
1H-imidazole 4-methaneamine sulphonamides are a class of imidazole-based antifungal agents
which inhibit fungal ergosterol synthesis in much the same manner as triazole-containing
antifungal drugs. Efforts have been made to try to understand how imidazole-based antifungal
agents interact at the target enzyme via the demethylase active site. An understanding of such
interaction should help in the design of more potent ergostreol synthesis inhibitors (Novel
antifungals based on 4-substituted imidazole: solid-phase synthesis of substituted aryl
sulfonamides towards optimisation of in vitro activity, A. K. Saha et. al., Bioorg. & Med.
Chem. Lett., 10, (2000), 2135-2139).
A library of 29 individual compounds, each purified by HPLC, was synthesised on 2-
chlorotrityl chloride polystyrene solid phase resin. Screening of these compounds against eight
isolates of Candida spp., revealed a number of active compounds. One of the most potent
compounds discovered was (i) which possessed an IC50 of 3 nM against ergosterol, and 163-
fold selectivity for inhibition of yeast sterol versus mammalian cholesterol synthesis. This
analogue was inactive against mould strains making it uniquely yeast active. A second active
compound (ii) demonstrated activity against the azole resistant strain C. albicans 1, and
possessed an IC50 of 15 nM against ergosterol. This library has been successful by the
continued optimisation of 4-substituted imidazole antifungals by high speed synthesis methods,
leading to highly yeast-selective as well as potent broad spectrum antifungal agents. These
molecules and their study may provide stimulus for further research towards the discovery of
clinically successful new antifungal drugs.
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Cholesterol ester transfer protein-mRNA ligands
A number of RNA oligonucleotide/ligand interactions have been characterised and described.
A 17-amino acid peptide containing the arginine-rich region of the human immunodeficiency
virus (HIV) Rev protein binds to Rev response element (RRE) RNA. Also, basic peptides
from the carboxy terminus of the human immunodeficiency virus type 1 (HIV-1) Tat protein
bind to the stem-loop region of transactivation response region TAR RNA. This peptide that
binds to TAR RNA has proven its biological activity by inhibition of HIV-1 replication in vivo.
Tripeptides that bind to the TAR RNA and inhibit gene expression could be isolated from
randomised pools of combinatorial libraries (Combinatorial synthesis of cholesterol ester
transfer protein mRNA ligands and screening by nodenaturating gel-electrophoresis, C.
Griesinger et. al., J. Med. Chem., 44, (2001), 2172-2177). A library of 625 compounds was
synthesised in mixtures of 25 on an M-Mal-PEG solid phase resin. Small peptide ligands were
found which bind to a 23-nt RNA oligonucleotide from the cholesterol ester transfer protein
mRNA. A 27-nt RNA oligonucleotide from the human immunodeficiency virus type-1 TAR
RNA was used to control the binding specificity. Gel-shift affinity screening was used to
extract the peptides with the best RNA binding properties. Following deconvolution of the
library, the peptide showing the most visible affinity for the 23-nt RNA was (iii) which gave a
binding constant Kd of 32 µM. This work has demonstrated that it is possible to obtain peptide
ligands for different RNA targets using a gel-shift assay. Also, elucidation of the minimum
pharmacophoric elements requirements for binding has been achieved, namely basic and
hydrophobic residues. This work lays the foundation for the design of more potent inhibitors
in the future.
(iii)
Lys-Tyr-Lys-Leu-Tyr-Lys-Cys-NH2
